タカダ タクマ   TAKADA Takuma
  髙田 卓磨
   所属   研究施設 研究施設
   職種   非常勤講師
論文種別 原著
言語種別 英語
査読の有無 査読あり
表題 Edoxaban for 12 Versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis According to Different Doses: Insights from the ONCO DVT study.
掲載誌名 正式名:European heart journal. Cardiovascular pharmacotherapy
略  称:Eur Heart J Cardiovasc Pharmacother
ISSNコード:20556845
掲載区分国外
巻・号・頁 pp.online
著者・共著者 Chatani Ryuki, Yamashita Yugo, Morimoto Takeshi, Muraoka Nao, Umetsu Michihisa, Nishimoto Yuji, Takada Takuma, Ogihara Yoshito, Nishikawa Tatsuya, Ikeda Nobutaka, Otsui Kazunori, Sueta Daisuke, Tsubata Yukari, Shoji Masaaki, Shikama Ayumi, Hosoi Yutaka, Tanabe Yasuhiro, Tsukahara Kengo, Nakanishi Naohiko, Kim Kitae, Ikeda Satoshi, Mushiake Kazunori, Kadota Kazushige, Ono Koh, Kimura Takeshi
発行年月 2024/04
概要 BACKGROUND:The ONCO DVT study revealed the superiority of 12-month relative to 3-month edoxaban treatment for cancer-associated isolated distal deep vein thrombosis (DVT) regarding the thrombotic risk.METHODS:In this pre-specified subgroup analysis of the ONCO DVT study, we stratified the patients into those with a standard edoxaban dose (60 mg/day; N=151) and those with a reduced edoxaban dose (30 mg/day; N=450) and evaluated the clinical outcomes for the 12-month and 3-month treatments.RESULTS:The cumulative 12-month incidence of symptomatic recurrent venous thromboembolism was lower in the 12-month than 3-month group for both the 60 mg (1.3% vs. 11.6%, P=0.02; odds ratio [OR], 0.12; 95% CI, 0.01-0.97) and 30 mg (1.1% vs. 7.6%, P=0.002; OR, 0.14; 95% CI, 0.03-0.60) edoxaban subgroups, which was consistent across the edoxaban doses without a significant interaction (P =0.90). The 12-month cumulative incidence of major bleeding was higher in the 12-month group than 3-month group for the 60 mg edoxaban subgroup (14.3% vs. 4.4%, P=0.046; OR, 3.61; 95% CI, 0.97-13.52), whereas it did not significantly differ between the two groups for the 30 mg edoxaban subgroup (8.7% vs. 8.6%, P=0.89; OR, 0.97; 95% CI, 0.49-1.91), signaling there was a potential interaction (P=0.07).CONCLUSIONS:A 12-month edoxaban regimen for cancer-associated isolated distal DVT was consistently superior to a 3-month regimen, across the edoxaban doses for the thrombotic risk. However, caution was suggested for the standard dose of edoxaban due to the potential for an increased risk of bleeding with prolonged anticoagulation therapy.
DOI 10.1093/ehjcvp/pvae028
PMID 38650055